Patricia Li
Family · Phoenix, AZNPI 1003579830
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 236 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,843 and has fallen 67.6% since, to $598 in 2025. Among family clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 236 payments — averaging $23.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$1K
- AstraZeneca$955
- AbbVie$911
- Viiv Healthcare Company$601
- Johnson & Johnson$567
- Janssen Products, LP$186
- plus $1K from 21 others
What the payments were for
- Food & beverage$5,43498%
- Education$852%
- Entertainment$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 66 | $1,013 |
| AstraZeneca(2 entities) | 20 | $955 |
| AbbVie | 34 | $911 |
| Viiv Healthcare Company | 22 | $601 |
| Johnson & Johnson(2 entities) | 29 | $567 |
| Janssen Products, LP | 2 | $186 |
| Pfizer | 12 | $178 |
| Novo Nordisk | 9 | $170 |
| Merck | 7 | $139 |
| Biohaven Pharmaceuticals, Inc. | 2 | $113 |
| Dynavax Technologies Corporation | 5 | $102 |
| Janssen Scientific Affairs, LLC | 1 | $96 |
| Boehringer Ingelheim | 4 | $73 |
| Hologic Sales And Service, LLC | 3 | $65 |
| Amgen | 3 | $52 |
| Abbott | 2 | $46 |
| GSK | 2 | $40 |
| Exact Sciences | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Lilly USA, LLC | 2 | $28 |
| Novartis | 1 | $25 |
| Nestle Healthcare Nutrition Inc. | 1 | $24 |
| Medtronic | 1 | $22 |
| Optos, Inc. | 1 | $21 |
| Verity Pharmaceuticals Inc. | 1 | $19 |
| Napo Pharmaceuticals Inc | 1 | $18 |
| Teleflex LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,541 in reported general payments places this provider in the 90th percentile of 4,119 family providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DescovyEmtricitabine/Tenofov Alafenam | 34 | $75,807 |
| OzempicSemaglutide | 53 | $61,303 |
| FarxigaDapagliflozin Propanediol | 16 | $26,541 |
| JardianceEmpagliflozin | 24 | $26,240 |
| EliquisApixaban | 15 | $18,528 |
| MounjaroTirzepatide | 17 | $18,188 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $10,489 |
| Midodrine Hcl | 12 | $4,392 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $2,034 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 79 | $1,826 |
| FenofibrateFenofibrate Nanocrystallized | 22 | $1,785 |
| SynthroidLevothyroxine Sodium | 23 | $1,660 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,480 |
| Fluticasone Propionate | 77 | $1,166 |
| ValacyclovirValacyclovir Hcl | 13 | $1,039 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadDescovy | $1,013 | $75,80734 claims |
| Novo NordiskOzempic | $170 | $61,30353 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $955 | $37,03128 claims |
| Boehringer IngelheimJardiance | $73 | $26,24024 claims |
| PfizerEliquis | $178 | $18,52815 claims |
| Lilly USA, LLCMounjaro | $28 | $18,18817 claims |
| AbbVieSynthroid | $911 | $1,66023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,119 family providers in Arizona.
Other family in Phoenix
- Kimberly HallaPhoenix$332K
- Audrey StevensonPhoenix$83K
- Rebekah EdwardsPhoenix$51K
- Tirsa QuartulloPhoenix$31K
- Jessica AcostaPhoenix$30K
- Stephanie JohnstonPhoenix$25K
- Kelly MarcelloPhoenix$23K
- Judith BergmanPhoenix$22K
- Lauren BonnerPhoenix$22K
- Rita GonzalezPhoenix$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.